Baolingbao Biology Co Ltd

Baolingbao released its 2026 interim report. The company's total operating revenue was 1.496 billion yuan, and net profit attributable to the parent was 82.3211 million yuan, a decrease of 10.3509 million yuan from the same period last year, down 11.17% year-on-year. Net cash inflow from operating activities was 119 million yuan, the asset-liability ratio was 23.07%, the gross margin was 14.65%, and diluted earnings per share was 0.22 yuan, down 12.00% year-on-year. The number of shareholders was 27,300, and the top ten shareholders held 36.72% of the total share capital.

Baolingbao released its 2026 interim report on August 26. Leveraging its three core businesses of prebiotics, dietary fiber, and sugar-reduction sweeteners, the company achieved operating revenue of 1.496 billion yuan in the reporting period, up 6.92 percent year on year. However, net profit attributable to the parent company was 82 million yuan, down 11.17 percent, and non-GAAP net profit was 73 million yuan, down 19.30 percent, showing a pattern of rising revenue but falling profit. Among these, revenue from the three core products grew 18.31 percent year on year, accounting for 64.48 percent of revenue after excluding feed and by-products, and contributing as much as 77.17 percent of gross profit. Dietary fiber revenue grew 35.37 percent, and overseas business revenue grew 34.84 percent. The decline in net profit was mainly affected by lower product selling prices, increased exchange losses, and share-based payment expenses. Excluding the impact of share-based payments, net profit was 103 million yuan, up 7.86 percent year on year. The company plans to distribute a cash dividend of 0.3 yuan per 10 shares, totaling about 11.4 million yuan. In addition, the second-phase project with an annual capacity of 20,000 tons of allulose has been completed and entered trial production, with total capacity expected to reach 30,000 tons by the end of the year.